nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Biological feasibility and importance of a gonorrhea vaccine for global public health
|
Vincent, Leah R. |
|
|
37 |
50 |
p. 7419-7426 |
artikel |
2 |
Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development
|
Schiffer, Joshua T. |
|
|
37 |
50 |
p. 7363-7371 |
artikel |
3 |
Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy
|
Hosangadi, Divya |
|
|
37 |
50 |
p. 7372-7380 |
artikel |
4 |
Defining a correlate of protection for chikungunya virus vaccines
|
Milligan, Gregg N. |
|
|
37 |
50 |
p. 7427-7436 |
artikel |
5 |
Editorial Board/Aims and Scope
|
|
|
|
37 |
50 |
p. IFC |
artikel |
6 |
Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics
|
Vekemans, Johan |
|
|
37 |
50 |
p. 7391-7393 |
artikel |
7 |
Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017
|
Gottlieb, Sami L. |
|
|
37 |
50 |
p. 7408-7418 |
artikel |
8 |
Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency
|
Vannice, K.S. |
|
|
37 |
50 |
p. 7443-7450 |
artikel |
9 |
Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25–26 April 2016
|
Giersing, Birgitte K. |
|
|
37 |
50 |
p. 7355-7362 |
artikel |
10 |
Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling
|
Gottlieb, Sami L. |
|
|
37 |
50 |
p. 7336-7345 |
artikel |
11 |
National Institute of Allergy and Infectious Diseases workshop report: “Chlamydia vaccines: The way forward”
|
Zhong, Guangming |
|
|
37 |
50 |
p. 7346-7354 |
artikel |
12 |
Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016
|
Giersing, Birgitte K. |
|
|
37 |
50 |
p. 7315-7327 |
artikel |
13 |
Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics
|
Vekemans, Johan |
|
|
37 |
50 |
p. 7394-7395 |
artikel |
14 |
Review of mathematical models of HSV-2 vaccination: Implications for vaccine development
|
Spicknall, Ian H. |
|
|
37 |
50 |
p. 7396-7407 |
artikel |
15 |
Status of vaccine research and development for Clostridium difficile
|
Riley, T.V. |
|
|
37 |
50 |
p. 7300-7306 |
artikel |
16 |
Status of vaccine research and development for Helicobacter pylori
|
Sutton, Philip |
|
|
37 |
50 |
p. 7295-7299 |
artikel |
17 |
Status of vaccine research and development of vaccines for Chlamydia trachomatis infection
|
Poston, Taylor B. |
|
|
37 |
50 |
p. 7289-7294 |
artikel |
18 |
The rotavirus vaccine development pipeline
|
Kirkwood, Carl D. |
|
|
37 |
50 |
p. 7328-7335 |
artikel |
19 |
Vaccination against the human cytomegalovirus
|
Plotkin, Stanley A. |
|
|
37 |
50 |
p. 7437-7442 |
artikel |
20 |
WHO consultation on ETEC and Shigella burden of disease, Geneva, 6–7th April 2017: Meeting report
|
Hosangadi, Divya |
|
|
37 |
50 |
p. 7381-7390 |
artikel |
21 |
WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016
|
Kobayashi, Miwako |
|
|
37 |
50 |
p. 7307-7314 |
artikel |